Ivacaftor deuterated: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

2026 Von Willebrand Disease clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Hemophilia B clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Hemophilia A clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Beta Thalassemia clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Sickle Cell Disease clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Cardiorenal Syndrome clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Acute Kidney Injury clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Portal Hypertension clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

Chlorhexidine gluconate/Metronidazole: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

HPC-Cord Blood (StemCyte): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

2026 Alcohol-Associated Hepatitis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…